Skip to content
OpenCapital
Get started

Tandem Diabetes Care TNDM Long-term portion of accrued product warranty

Other financials

Income statement

See full
Revenue$247.2M+5.5%
Gross profit$136.8M+15.5%
Operating income-$17.4M+85.6%
Net income-$20.4M+84.4%
EPS (diluted)-$0.30+84.8%

Balance sheet

See full
Cash & equivalents$179.3M+235%
Total debt$734.7M+49.0%
Total equity$132.4M-14.7%
Total assets$1.2B+25.1%

Cash flow

See full
Operating cash flow$11.1M+160%
CapEx$6.3M+111%
Free cash flow$4.8M+123%

Valuation

See full
Market cap$1.08B-19.8%
Enterprise value$1.64B-8.5%
P/S1.1×-0.3×

Profitability

See full
Gross margin54.9%+2.7pp
Operating margin-8.2%-2.9pp
Net margin-9.2%-3.1pp
FCF margin-0.8%-0.4pp

Returns & leverage

See full
Return on equity-65.7%-14.7pp
Debt / equity5.5×+2.4×
Current ratio3.6×+1.3×

Where this comes from

Reported directly by Tandem Diabetes Care in its filing.

Tagged under the XBRL concept us-gaap:ProductWarrantyAccrualNoncurrent.

The official record: Tandem Diabetes Care’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Tandem Diabetes Care's long-term portion of accrued product warranty.

Connect your AI assistant and see it in context, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Tandem Diabetes Care's long-term portion of accrued product warranty?
Tandem Diabetes Care (TNDM) reported long-term portion of accrued product warranty of $21.92M in Q1 2026.
How has Tandem Diabetes Care's long-term portion of accrued product warranty changed year-over-year?
Tandem Diabetes Care's long-term portion of accrued product warranty increased by 4.5% year-over-year, from $20.99M to $21.92M.
What is the long-term trend for Tandem Diabetes Care's long-term portion of accrued product warranty?
Over 5 years (2020 to 2025), Tandem Diabetes Care's long-term portion of accrued product warranty has grown at a 10.0% compound annual growth rate (CAGR), from $13.67M to $22.04M.